Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals is the lead sponsor of 3 current clinical trials in our UK and USA registers. 3 are recruiting patients now. The most common phase is Phase 1. The most-studied condition is Relapsed or Refractory B-cell Malignancies.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06980116 · Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL)
|
Phase 1 | Recruiting | 2025-03 | UK |
|
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT05985655 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC)
|
Phase 1/2 | Recruiting | 2023-07 | UK, USA |
|
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
NCT07517198 · ClinicalTrials.gov ↗ · Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer
|
Phase 1 | Recruiting | 2026-04 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in UK | 2 | 2 |
| Clinical trials in USA | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals is the lead sponsor of 3 current trials on ClinicalTrials.gov in our UK and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of its 3 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.